Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01 B : A Phase 1/2a HIV-1 Vaccine Trial.

MLA

Garrett, Nigel, et al. “Safety and Immunogenicity of a DNA Vaccine With Subtype C Gp120 Protein Adjuvanted With MF59 or AS01 B : A Phase 1/2a HIV-1 Vaccine Trial.” JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 96, no. 4, Aug. 2024, pp. 350–60. EBSCOhost, https://doi.org/10.1097/QAI.0000000000003438.

APA

Garrett, N., Dintwe, O., Monaco, C. L., Jones, M., Seaton, K. E., Church, E. C., Grunenberg, N., Hutter, J., deCamp, A., Huang, Y., Lu, H., Mann, P., Robinson, S. T., Heptinstall, J., Jensen, R. L., Pantaleo, G., Ding, S., Koutsoukos, M., Hosseinipour, M. C., & Van Der Meeren, O. (2024). Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01 B : A Phase 1/2a HIV-1 Vaccine Trial. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 96(4), 350–360. https://doi.org/10.1097/QAI.0000000000003438

Chicago

Garrett, Nigel, One Dintwe, Cynthia L. Monaco, Megan Jones, Kelly E. Seaton, E. Chandler Church, Nicole Grunenberg, et al. 2024. “Safety and Immunogenicity of a DNA Vaccine With Subtype C Gp120 Protein Adjuvanted With MF59 or AS01 B : A Phase 1/2a HIV-1 Vaccine Trial.” JAIDS: Journal of Acquired Immune Deficiency Syndromes 96 (4): 350–60. doi:10.1097/QAI.0000000000003438.